I appreciate your thoughts and in no way suggest a cheap takeover. With the experience of NH, he would approach the table as an equal and further the interest in the company. While I agree with your point about an ART launch generating a higher price, you must concede the point that it is a long held practice by big pharma to buy out a firm with drugs in the development stage. And, as I know you are aware, they do this because they may hold capabilities that would spur development and approval, enable manufacturing, further distribution, or all the above.